Soterix Medical Inc. (SMI) was formed to develop and deploy innovative medical treatments focused on neuropsychiatric and neurological disorders and rehabilitation. Founded in 2008, SMI is the world leader in clinical trials for non-invasive neuromodulation working with over 850 medical centers in the US and worldwide. SMI has licensed and developed a comprehensive intellectual property portfolio that includes High-Definition transcranial Direct Current Stimulation (HD-tDCS), Limited Total Energy tDCS (LTE-tDCS), and Neurotargeting. From the most targeted non-invasive clinical systems to the most portable units, Soterix Medical provides clinicians and patients with unique and adaptable solutions. While ongoing HD-tDCS and LTE-tDCS trials use investigational devices that are regulated/limited by US or Federal law, SMI has secured multiple clinical approvals worldwide (EU-CE; Canada-Health Canada; Brazil-Anvisa; Australia-TGA, etc.). SMI is also diversified to distribute synergistic technologies and provides services in image analysis, modeling,consumer product human factors, as well as defense and space applications. SMI currently holds multiple US clinical clearances on synergistic technologies. SMI is proudly based in the Tri-state area with international distributors in all major markets.
At Soterix Medical, Engineering Serving Humanity means that we are committed to bring the most advanced medical technology into the hands of people who need it. The commitment underpins everything we do.
1480 U.S. 9N,WOODBRIDGE, NJ 07095
ISO 13485:2016 certifiedMDSAP certifiedFDA Registered Facility
Rated for up to 2 mA and up to 30 minutes.
Only approved Soterix Medical HD-Holders, HD-Electrodes, and HD-GELs are validated. Allows generic integration with most EEG commercial systems.
1 HD1 Electrode Holder
Base Diameter: 24 mm
Height: 13 mm
Manual & Specifications
4x1 HD Adaptor
MxN-5 / MxN-9 HD
MxN 33/65 HD
1x1 Platforms (special cables required)